this stage of my career,” said Dr. Dean. “What excites me most is the caliber of the team and the chance to build a drug discovery and development platform that bridges cutting-edge science with real-world impact for patients.” About Odyssey...
UCB, a global biopharmaceutical company, announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only medicine approved to selectively inhibit...
medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play...
is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the...
CTIBIOTECH™ is a biotechnology company specializing in the development of advanced human tissue models for research, drug discovery and cosmetic testing. Using state-of-the-art bioprinting and tissue engineering techniques, CTIBIOTECH creates...
Mission Bio, a leader in single-cell multi-omics for precision medicine, announced the appointment of Zivjena Vucetic, M.D., Ph.D., as Chief Medical Officer. A physician-scientist with more than 15 years of experience in diagnostics and emerging...
BioArctic AB's partner Eisai announced that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National Medical Products Administration (NMPA)...
Sanguine Biosciences, a leading provider of healthy and disease-state human biospecimens and data for research, today announced the expansion of its oncology sample offerings through new partnerships with oncology clinics nationwide. These...
Sadler, Chief Commercial Officer at Medicines Discovery Catapult, said: “MDC operates an advanced preclinical drug discovery facility, including world-class radiochemistry capabilities and a translational suite of imaging technologies, to support...
SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted. Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for...
and others. Dash Bio's mission is bold but urgent: to rebuild drug development for a modern biotech era. While drug discovery has seen massive innovation through AI, mRNA, and CRISPR, drug development — the 7–12 year, multi-billion-dollar black...
BD (Becton, Dickinson and Company) a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The...
Duality Biotherapeutics' partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical...
Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide...
launch joint space missions focused on high-throughput biotechnology research. High-throughput screening (HTS) is a drug discovery process that allows for the rapid testing of thousands of chemical compounds to identify potential new medicines. The...
The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a new Team Science Award and an Early Career...
Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics...
(CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development. Organoids are three-dimensional cell culture systems engineered to closely mimic human organs, offering...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform. iXCells’ mission is to empower...
Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class...
